Multivariate meta-analysis has potential over its univariate counterpart. The most common challenge in univariate or multivariate meta-analysis is estimating heterogeneity parameters in non-negative domains under the random-effects model assumption. In this context, two new multivariate estimation methods are demonstrated; first, by extending the Sidik and Jonkman (2005) univariate estimates to a multivariate setting, and second, by considering an iterative version of the Sidik and Jonkman method, namely, a method developed in Wouhib (2013). These two methods are compared with extended DerSimonian and Laird methods (Jackson et al. 2009; Chen et al. 2012) by using an example and simulation in random-effects multivariate meta-analysis. Finally, the benefits of the proposed estimates are evaluated in terms of precision in estimating vectors of effect sizes and associated covariance matrices via simulation. Also, some limitations and remedies resulting from negative definite matrix in estimating heterogeneity parameters will be discussed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875117 | PMC |
http://dx.doi.org/10.2991/jsta.2014.13.1.5 | DOI Listing |
Eur Heart J Digit Health
January 2025
Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA.
Aims: Accurate prediction of clinical outcomes following percutaneous coronary intervention (PCI) is essential for mitigating risk and peri-procedural planning. Traditional risk models have demonstrated a modest predictive value. Machine learning (ML) models offer an alternative risk stratification that may provide improved predictive accuracy.
View Article and Find Full Text PDFFront Pharmacol
January 2025
Department of Cardiovascular Surgery, Affiliated Hospital of Southwest Jiaotong University, The General Hospital of Western Theater Command, Chengdu, China.
Background: Anticoagulants are the primary means for the treatment and prevention of venous thromboembolism (VTE), but their clinical standardized application still remains controversial. The present study intends to comprehensively compare the efficacy and safety of various anticoagulants in VTE.
Methods: Medline, Embase, and Cochrane Library from their inception up to August 2023 were searched to compare the efficacy and safety of various anticoagulants in VTE.
Cardiovasc Diabetol
January 2025
Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, North Kargar Ave, Tehran, 1995614331, Iran.
Background: Atherogenic index of plasma (AIP), a novel logarithmic index that combines fasting triglyceride and high-density lipoprotein cholesterol concentrations, is associated with the burden of atherosclerosis. This study aimed to evaluate the relationship between AIP and coronary artery disease (CAD) risk, severity, and prognosis in populations with and without established CAD.
Methods: PubMed, Embase, and Web of Science were systematically searched from the inception of each database to August 13, 2024.
Cardiovasc Diabetol
January 2025
Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou Institute of Cardiovascular Diseases, Zhejiang Key Laboratory of Medical Epigenetics, School of Basic Medical Sciences, Zhejiang Key Laboratory for Research in Assessment of Cognitive Impairments, Hangzhou Normal University, Hangzhou, 310015, China.
Background: Numerous studies have shown that insulin resistance (IR) is closely related to the pathogenesis of cardiovascular disease (CVD). This study aims to summarize the correlation between the triglyceride-glucose-body mass index (TyG-BMI index), a novel surrogate indicator of insulin resistance, and the incidence of CVD in patients without CVD at baseline through meta-analysis.
Method: Cohort studies assessing multivariate-corrected hazard ratios (HRs) for associations between the TyG-BMI index and cardiovascular disease (CVD) were obtained by searching PubMed, Cochrane Library, EMBASE, and Web of Science.
Front Neurol
January 2025
Department of Pharmacy, Aerospace Center Hospital, Beijing, China.
Objective: To systematically compare the benefits and risks of all thrombolytic agents (tenecteplase, reteplase, and alteplase) at different doses for thrombolytic therapy in patients with acute ischemic stroke (AIS).
Background: Alteplase is the cornerstone treatment for AIS, but alternative thrombolytic agents are needed. The efficacy and safety of tenecteplase and reteplase, compared to alteplase, remain unclear, as does the optimal dosing for these treatments.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!